1. At a Glance – The Jelly That Doesn’t Jiggle
India Gelatine & Chemicals Ltd is currently sitting at ₹358 with a market cap of ₹254 crore. The stock hasn’t done much in the last 3 months (-0.07%), but the numbers underneath? That’s where things get interesting.
Quarter ended December 2025 delivered:
- Sales: ₹44.83 crore
- PAT: ₹7.10 crore
- EPS: ₹10.01
- Profit growth YoY: 99.4%
- OPM: 17.13%
And the best part? The stock trades at a P/E of 9.64 while the industry median P/E is 27.8.
Return on Capital Employed: 11.9%
ROE: 9.22%
Debt to Equity: 0.03 (basically no drama)
Dividend Yield: 1.40%
So let’s get this straight — a company doubling quarterly profit, trading at single-digit P/E, almost debt free, and sitting in a niche specialty chemical space.
Is this market inefficiency or is the jelly too soft to hold shape?
Let’s dig in.
2. Introduction – From Bones to Business
Incorporated in 1973, India Gelatine & Chemicals Ltd manufactures Ossein, Di-Calcium Phosphate (DCP) and various forms of Gelatine.
Yes. The same gelatin that goes into:
- Your capsules
- Your dessert
- Your cosmetics
- Your photographic film
- And even matchsticks
This isn’t some startup AI fantasy story. This is an old-school, asset-heavy, raw-material-intensive chemical manufacturer.
But here’s where the story gets spicy.
In FY25, the company delivered:
- Revenue: ₹199 crore
- Net Profit: ₹17 crore
And in TTM:
- Revenue: ₹184 crore
- Net Profit: ₹26 crore
Profit up. Sales down.
Welcome to the magical world of margin expansion.
But the real masala? There was an open offer in March–April 2025 at ₹408.90 per share. That’s higher than today’s ₹358.
So someone was ready to pay ₹408.90.
Now ask yourself — why?
3. Business Model – WTF Do They Even Do?
Let me explain this like you’re a smart but lazy investor.
India Gelatine collects animal bones.
Extracts collagen.
Processes it into:
- Edible Gelatine
- Pharmaceutical Gelatine
- Technical Gelatine
- Photographic Gelatine
- DCP (used in animal feed)
This gelatin then goes into:
